Canada markets open in 5 hours 46 minutes

Clearside Biomedical, Inc. (CLSD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.0100-0.0200 (-1.94%)
At close: 04:00PM EST
1.0400 +0.03 (+2.97%)
After hours: 05:11PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.0300
Open1.0200
Bid0.0000 x 1000
Ask0.0000 x 900
Day's Range1.0100 - 1.0500
52 Week Range0.6500 - 1.8500
Volume44,611
Avg. Volume117,079
Market Cap63.033M
Beta (5Y Monthly)2.18
PE Ratio (TTM)N/A
EPS (TTM)-0.6100
Earnings DateNov 13, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.67
  • Insider Monkey

    Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript

    Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript November 13, 2023 Clearside Biomedical, Inc. beats earnings expectations. Reported EPS is $-0.15, expectations were $-0.16. Operator: Greetings, and welcome to the Clearside Biomedical Third Quarter 2023 Financial Results and Corporate Update Call. At this time, all participants are in a listen-only mode and a question-and-answer […]

  • GlobeNewswire

    Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

    - New Licensing Partnership with BioCryst Pharmaceuticals Expands Clearside’s Proprietary Suprachoroidal Injection Platform to Plasma Kallikrein Inhibitor - - BioCryst Collaboration Provides $5 Million Upfront, the Potential for Additional $77.5 Million in Clinical, Regulatory, and Sales Based Milestone Payments, Plus Royalties - - Recruitment Completed in CLS-AX Phase 2b ODYSSEY Wet AMD Trial with Topline Data Expected in Q3 2024 - - Management to Host Webcast and Conference Call Today at 4:30

  • GlobeNewswire

    Clearside Biomedical to Participate in Fireside Chat at the Stifel 2023 Healthcare Conference

    ALPHARETTA, Ga., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that George Lasezkay, Pharm.D., J.D., President and Chief Executive Officer, will participate in a fireside chat at the Stifel 2023 Healthcare Conference on Wednesday, November 15, 2023 at 8:35 a.m. ET in New York, NY. A link to the live and archived webca